Biotech company EFG conducts scientific research, and develops and produces a wide variety of medicines derived from living organisms, but mostly focuses on neurological applications. Because of the generally longer time span it takes biotech companies to create these products $($compared to pharmaceutical companies$),$ EFG's new CEO has required her financial staff to periodically determine how long it takes EFG to meet its obligations.

If the most recent figures for the average payment period indicate a ratio for the $3$rd quarter of $2023=71\mathrm{.}4,$ while it was $83\mathrm{.}4$ during the $2$nd quarter of $2023,88\mathrm{.}9$ during the $1$st quarter of $2023,$ and $89\mathrm{.}2$ during the last quarter of $2021,$ then that generally means $\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.$

Group of answer choices

EFG is presently spending less in interest payments for its obligations.

EFG is presently spending more in interest payments for its obligations.

EFG is presently taking the same amount of time to repay its obligations.

EFG is presently spending about the same in interest payments for its obligations.

EFG is presently taking more time to repay its obligations.

EFG is presently taking less time to repay its obligations.